NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive than symptomatic treatments, offer substantial long-term cost benefits by ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

We studied multiplex IgAN kindreds from Italy (24 kindreds) and the United States (6 kindreds). All were ascertained through biopsy-documented IgAN cases and had at least one more affected member.

ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Today, on IgA Nephropathy Awareness Day, the American Kidney Fund (AKF) proudly announces the creation of new educational resources for "A Step Ahead ...

Four hours after her surprising defeat to Danielle Collins at the Italian Open in Rome, Iga Swiatek finally faced the press. It is unusual for any player to take that long after a match to give a ...

Iga Swiatek explained what went wrong during her match against Danielle Collins at the Italian Open and discussed Roland Garros. / IMAGO / NurPhoto Iga Swiatek's clay court season went from bad to ...